# Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

> **NCT03139916** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 36 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Bavituximab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03139916
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-13
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139916, "Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03139916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*